Novo Holdings A/S’s Inozyme Pharma INZY Stock Holding History

Novo Holdings A/S’s Portfolio INZY Stock Details INZY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,867,706	Closed	-$31.8M	–	51
2021 Q2	$31.8M	Sell	1,867,706 -101,673	-5%	-$1.77M	1.41%	20
2021 Q1	$39M	Sell	1,969,379 -600,000	-23%	-$13.2M	1.61%	17
2020 Q4	$53M	Hold	2,569,379	–	–	2.27%	13
2020 Q3	$67.5M	Buy	+2,569,379	New	+$63.8M	3.35%	11

Other funds holding INZY

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

PBPIA

Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Novo Holdings A/S's INZY Position: Q3 2021 in Review

Novo Holdings A/S sold out of Inozyme Pharma (INZY) in Q3 2021, closing a stake of 1,867,706 shares — an estimated $31.8M sold.

Novo Holdings A/S first reported a position in INZY in Q3 2020 and held it in 4 quarters. The position peaked at $67.5M in Q3 2020. 52 funds tracked by Wall St. Rank hold INZY as of Q3 2021.

Novo Holdings A/S reported no remaining Inozyme Pharma position as of Q3 2021 after selling out during the quarter.
Novo Holdings A/S sold 1,867,706 Inozyme Pharma shares in Q3 2021, an estimated $31.8M.
Novo Holdings A/S first reported a position in Inozyme Pharma in Q3 2020 and held it in 4 quarters.
Novo Holdings A/S's Inozyme Pharma position peaked at $67.5M in Q3 2020.
52 funds tracked by Wall St. Rank held Inozyme Pharma as of Q3 2021.

Based on Novo Holdings A/S's 13F filing for Q3 2021, filed 15 Nov 2021.